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Effects of  Vitamin E in Non Alcoholic Fatty Liver Disease 
Background  
 Nonalcoholic fatty liver disease(NAFLD) is a common liver disease that can 
progress to cirrhosis and account for about one third of cases of chronic liver disease. 
There is a strong association  of NAFLD with insulin resistance and the metabolic 
syndrome. Macrosteatosis followed by oxidative stress explains the pathophysiology 
of  NAFLD and disease progression. Currently there is no established treatment for 
this disease. 
 Vitamin E being an antioxidant helps in decreasing the oxidative stress and has 
been evaluated for use in NAFLD. 
Objective  
 To determine  the  changes in the grade of fatty infiltration of liver in ultra 
sonogram and changes in liver enzymes supplemented with  vitamin E. 
Methods  
 Single centre, prospective, open label, single arm   study conducted  for  a  
period  of  12  weeks ,conducted at Medicine outpatient department, Government 
Stanley Medical College and Hospital, Chennai-1 
 Patients attending OPD with any of the features of the metabolic syndrome 
were  screened for non alcoholic fatty liver disease by means of  detailed medical 
history, drug history, alcohol intake, clinical examination followed by ultrasonogram 
imaging and biochemical tests. 
 A total of  60 patients were placed in a single arm and were given capsule 
vitamin E 600 mg orally once daily for a period of 12 weeks along with the drugs that 
participant is already taking for type 2 diabetes mellitus, hypertension and 
dyslipidemia. 
  The primary outcome measure was the change in grade of  fatty infiltration of 
liver in ultrasonogram at the end of  12 weeks of treatment with vitamin E. Other 
outcome measures are changes in liver size by ultrasonogram, changes in liver 
enzymes, lipid profile. 
Results 
 Treatment with vitamin E resulted in a significant decrease in grades of liver 
echogenicity ( p<0.05) and decrease in liver size (p<0.05). At baseline elevation in 
AST and ALT levels were  less than 2 times of normal values. The AST : ALT levels 
is less than 1, suggesting mild disease.  At the end of 12 weeks serum AST and ALT 
levels showed significant reduction( p< 0.05). Results also showed a  significant 
reduction in lipid profile values of total cholesterol, LDL, Triglyceride levels  at the 
end of  study (p<0.05). There was no significant changes in BMI, waist circumference 
and body weight. Vitamin E therapy was associated with only few mild adverse 
effects. 
 
Conclusion  
 Vitamin E an anti oxidant, membrane stabiliser,  adjuvant hypolipidemic drug,  
is a well tolerated effective pharmacotherapeutic  agent for Non Alcoholic Fatty Liver 
Disease with lesser adverse events.  
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